nodes	percent_of_prediction	percent_of_DWPC	metapath
Tacrolimus—Liver fatty—Octreotide—thymus cancer	0.0404	0.0574	CcSEcCtD
Tacrolimus—Otitis—Octreotide—thymus cancer	0.0292	0.0415	CcSEcCtD
Tacrolimus—Basal cell carcinoma—Octreotide—thymus cancer	0.0215	0.0306	CcSEcCtD
Tacrolimus—Hepatic steatosis—Octreotide—thymus cancer	0.0168	0.0238	CcSEcCtD
Tacrolimus—Breast neoplasm—Octreotide—thymus cancer	0.0168	0.0238	CcSEcCtD
Tacrolimus—Hypochromic anaemia—Octreotide—thymus cancer	0.0131	0.0186	CcSEcCtD
Tacrolimus—ABCA5—cardiac atrium—thymus cancer	0.0121	0.0461	CbGeAlD
Tacrolimus—Ear infection—Octreotide—thymus cancer	0.0119	0.0169	CcSEcCtD
Tacrolimus—ABCA5—pituitary gland—thymus cancer	0.0118	0.045	CbGeAlD
Tacrolimus—Pancreatitis acute—Octreotide—thymus cancer	0.011	0.0156	CcSEcCtD
Tacrolimus—Hernia—Octreotide—thymus cancer	0.0108	0.0154	CcSEcCtD
Tacrolimus—PPP3CA—hematopoietic system—thymus cancer	0.0107	0.041	CbGeAlD
Tacrolimus—MTOR—neck—thymus cancer	0.0106	0.0407	CbGeAlD
Tacrolimus—Abdominal bloating—Octreotide—thymus cancer	0.0106	0.0151	CcSEcCtD
Tacrolimus—Rectal disorder—Octreotide—thymus cancer	0.0103	0.0147	CcSEcCtD
Tacrolimus—ABCA5—bone marrow—thymus cancer	0.0102	0.0389	CbGeAlD
Tacrolimus—ABCA5—thyroid gland—thymus cancer	0.0102	0.0388	CbGeAlD
Tacrolimus—Anorectal disorder—Octreotide—thymus cancer	0.00964	0.0137	CcSEcCtD
Tacrolimus—FKBP1A—neck—thymus cancer	0.00957	0.0366	CbGeAlD
Tacrolimus—Ear disorder—Octreotide—thymus cancer	0.00939	0.0133	CcSEcCtD
Tacrolimus—ABCA5—lung—thymus cancer	0.00922	0.0353	CbGeAlD
Tacrolimus—Loose stools—Octreotide—thymus cancer	0.00915	0.013	CcSEcCtD
Tacrolimus—PPP3CA—cardiac atrium—thymus cancer	0.00814	0.0311	CbGeAlD
Tacrolimus—PPP3CA—pituitary gland—thymus cancer	0.00796	0.0304	CbGeAlD
Tacrolimus—MTOR—hematopoietic system—thymus cancer	0.00792	0.0303	CbGeAlD
Tacrolimus—Hypothyroidism—Octreotide—thymus cancer	0.00789	0.0112	CcSEcCtD
Tacrolimus—Nail disorder—Octreotide—thymus cancer	0.00781	0.0111	CcSEcCtD
Tacrolimus—PPP3CA—lymphoid tissue—thymus cancer	0.00755	0.0289	CbGeAlD
Tacrolimus—Intestinal obstruction—Octreotide—thymus cancer	0.00743	0.0106	CcSEcCtD
Tacrolimus—Seborrhoeic dermatitis—Octreotide—thymus cancer	0.00743	0.0106	CcSEcCtD
Tacrolimus—Neuralgia—Octreotide—thymus cancer	0.00729	0.0104	CcSEcCtD
Tacrolimus—Burning sensation—Octreotide—thymus cancer	0.00729	0.0104	CcSEcCtD
Tacrolimus—MTOR—epithelium—thymus cancer	0.00724	0.0277	CbGeAlD
Tacrolimus—FKBP1A—hematopoietic system—thymus cancer	0.00713	0.0272	CbGeAlD
Tacrolimus—Influenza-like symptoms—Octreotide—thymus cancer	0.00709	0.0101	CcSEcCtD
Tacrolimus—PPP3CA—bone marrow—thymus cancer	0.00688	0.0263	CbGeAlD
Tacrolimus—PPP3CA—thyroid gland—thymus cancer	0.00686	0.0262	CbGeAlD
Tacrolimus—Herpes zoster—Octreotide—thymus cancer	0.00673	0.00956	CcSEcCtD
Tacrolimus—Cholestasis—Octreotide—thymus cancer	0.00667	0.00948	CcSEcCtD
Tacrolimus—FKBP1A—epithelium—thymus cancer	0.00651	0.0249	CbGeAlD
Tacrolimus—Otitis media—Octreotide—thymus cancer	0.00651	0.00925	CcSEcCtD
Tacrolimus—Coagulopathy—Octreotide—thymus cancer	0.00651	0.00925	CcSEcCtD
Tacrolimus—ABCA5—lymph node—thymus cancer	0.00631	0.0241	CbGeAlD
Tacrolimus—PPP3CA—lung—thymus cancer	0.00623	0.0238	CbGeAlD
Tacrolimus—Endocrine disorder—Octreotide—thymus cancer	0.00611	0.00869	CcSEcCtD
Tacrolimus—Acne—Octreotide—thymus cancer	0.00602	0.00856	CcSEcCtD
Tacrolimus—Neoplasm malignant—Octreotide—thymus cancer	0.00593	0.00843	CcSEcCtD
Tacrolimus—MTOR—pituitary gland—thymus cancer	0.00588	0.0225	CbGeAlD
Tacrolimus—Jaundice cholestatic—Octreotide—thymus cancer	0.00577	0.0082	CcSEcCtD
Tacrolimus—ORM1—hematopoietic system—thymus cancer	0.00558	0.0213	CbGeAlD
Tacrolimus—MTOR—lymphoid tissue—thymus cancer	0.00558	0.0213	CbGeAlD
Tacrolimus—Hyperbilirubinaemia—Octreotide—thymus cancer	0.00557	0.00792	CcSEcCtD
Tacrolimus—Arthropathy—Octreotide—thymus cancer	0.00557	0.00792	CcSEcCtD
Tacrolimus—Cellulitis—Octreotide—thymus cancer	0.00557	0.00792	CcSEcCtD
Tacrolimus—Herpes simplex—Octreotide—thymus cancer	0.0055	0.00781	CcSEcCtD
Tacrolimus—FKBP1A—cardiac atrium—thymus cancer	0.00541	0.0207	CbGeAlD
Tacrolimus—Hearing impaired—Octreotide—thymus cancer	0.00532	0.00757	CcSEcCtD
Tacrolimus—FKBP1A—pituitary gland—thymus cancer	0.00529	0.0202	CbGeAlD
Tacrolimus—MTOR—bone marrow—thymus cancer	0.00508	0.0194	CbGeAlD
Tacrolimus—Phosphatase alkaline increased—Octreotide—thymus cancer	0.00507	0.0072	CcSEcCtD
Tacrolimus—Vaginal inflammation—Octreotide—thymus cancer	0.00507	0.0072	CcSEcCtD
Tacrolimus—MTOR—thyroid gland—thymus cancer	0.00507	0.0194	CbGeAlD
Tacrolimus—FKBP1A—lymphoid tissue—thymus cancer	0.00502	0.0192	CbGeAlD
Tacrolimus—Hyperkalaemia—Octreotide—thymus cancer	0.00498	0.00708	CcSEcCtD
Tacrolimus—Cystitis noninfective—Octreotide—thymus cancer	0.00495	0.00703	CcSEcCtD
Tacrolimus—Influenza like illness—Octreotide—thymus cancer	0.00492	0.00699	CcSEcCtD
Tacrolimus—Cystitis—Octreotide—thymus cancer	0.00489	0.00695	CcSEcCtD
Tacrolimus—Candida infection—Octreotide—thymus cancer	0.00484	0.00688	CcSEcCtD
Tacrolimus—Vaginal infection—Octreotide—thymus cancer	0.00478	0.0068	CcSEcCtD
Tacrolimus—Neuropathy—Octreotide—thymus cancer	0.00476	0.00676	CcSEcCtD
Tacrolimus—Cramps of lower extremities—Octreotide—thymus cancer	0.00465	0.00662	CcSEcCtD
Tacrolimus—MTOR—lung—thymus cancer	0.0046	0.0176	CbGeAlD
Tacrolimus—Mouth ulceration—Octreotide—thymus cancer	0.00458	0.00651	CcSEcCtD
Tacrolimus—Bladder pain—Octreotide—thymus cancer	0.00458	0.00651	CcSEcCtD
Tacrolimus—FKBP1A—bone marrow—thymus cancer	0.00457	0.0175	CbGeAlD
Tacrolimus—FKBP1A—thyroid gland—thymus cancer	0.00456	0.0174	CbGeAlD
Tacrolimus—Phlebitis—Octreotide—thymus cancer	0.00427	0.00607	CcSEcCtD
Tacrolimus—PPP3CA—lymph node—thymus cancer	0.00426	0.0163	CbGeAlD
Tacrolimus—Thrombophlebitis—Octreotide—thymus cancer	0.00425	0.00604	CcSEcCtD
Tacrolimus—Diabetes mellitus—Octreotide—thymus cancer	0.00423	0.00601	CcSEcCtD
Tacrolimus—Blood alkaline phosphatase increased—Octreotide—thymus cancer	0.00423	0.00601	CcSEcCtD
Tacrolimus—Gastroenteritis—Octreotide—thymus cancer	0.00415	0.0059	CcSEcCtD
Tacrolimus—FKBP1A—lung—thymus cancer	0.00414	0.0158	CbGeAlD
Tacrolimus—Deafness—Octreotide—thymus cancer	0.00411	0.00584	CcSEcCtD
Tacrolimus—Cardiac failure congestive—Octreotide—thymus cancer	0.00406	0.00576	CcSEcCtD
Tacrolimus—Nasal congestion—Octreotide—thymus cancer	0.00404	0.00574	CcSEcCtD
Tacrolimus—Injury—Octreotide—thymus cancer	0.004	0.00569	CcSEcCtD
Tacrolimus—Hot flush—Octreotide—thymus cancer	0.00393	0.00559	CcSEcCtD
Tacrolimus—Amnesia—Octreotide—thymus cancer	0.00391	0.00556	CcSEcCtD
Tacrolimus—Menopausal symptoms—Octreotide—thymus cancer	0.0039	0.00554	CcSEcCtD
Tacrolimus—Anaphylactoid reaction—Octreotide—thymus cancer	0.0038	0.0054	CcSEcCtD
Tacrolimus—Arthritis—Octreotide—thymus cancer	0.00378	0.00538	CcSEcCtD
Tacrolimus—Hypoglycaemia—Octreotide—thymus cancer	0.00377	0.00536	CcSEcCtD
Tacrolimus—Gastrointestinal haemorrhage—Octreotide—thymus cancer	0.00368	0.00523	CcSEcCtD
Tacrolimus—Osteoarthritis—Octreotide—thymus cancer	0.00368	0.00523	CcSEcCtD
Tacrolimus—Pain in extremity—Octreotide—thymus cancer	0.00368	0.00523	CcSEcCtD
Tacrolimus—Psychotic disorder—Octreotide—thymus cancer	0.00359	0.00511	CcSEcCtD
Tacrolimus—ORM1—bone marrow—thymus cancer	0.00358	0.0137	CbGeAlD
Tacrolimus—Dehydration—Octreotide—thymus cancer	0.00342	0.00486	CcSEcCtD
Tacrolimus—Dry skin—Octreotide—thymus cancer	0.00337	0.00479	CcSEcCtD
Tacrolimus—Cramp muscle—Octreotide—thymus cancer	0.00331	0.00471	CcSEcCtD
Tacrolimus—Gastritis—Octreotide—thymus cancer	0.00326	0.00463	CcSEcCtD
Tacrolimus—Muscular weakness—Octreotide—thymus cancer	0.00324	0.00461	CcSEcCtD
Tacrolimus—ORM1—lung—thymus cancer	0.00324	0.0124	CbGeAlD
Tacrolimus—Abdominal distension—Octreotide—thymus cancer	0.0032	0.00455	CcSEcCtD
Tacrolimus—Asthma—Octreotide—thymus cancer	0.00318	0.00452	CcSEcCtD
Tacrolimus—Influenza—Octreotide—thymus cancer	0.00318	0.00452	CcSEcCtD
Tacrolimus—MTOR—lymph node—thymus cancer	0.00315	0.012	CbGeAlD
Tacrolimus—Pancreatitis—Octreotide—thymus cancer	0.00312	0.00443	CcSEcCtD
Tacrolimus—CYP3A5—hematopoietic system—thymus cancer	0.0031	0.0119	CbGeAlD
Tacrolimus—Sweating increased—Octreotide—thymus cancer	0.0031	0.0044	CcSEcCtD
Tacrolimus—Bronchitis—Octreotide—thymus cancer	0.00306	0.00435	CcSEcCtD
Tacrolimus—Dysuria—Octreotide—thymus cancer	0.00297	0.00422	CcSEcCtD
Tacrolimus—Pollakiuria—Octreotide—thymus cancer	0.00294	0.00417	CcSEcCtD
Tacrolimus—Weight increased—Octreotide—thymus cancer	0.00289	0.00411	CcSEcCtD
Tacrolimus—Weight decreased—Octreotide—thymus cancer	0.00288	0.00409	CcSEcCtD
Tacrolimus—Hyperglycaemia—Octreotide—thymus cancer	0.00287	0.00408	CcSEcCtD
Tacrolimus—Pneumonia—Octreotide—thymus cancer	0.00285	0.00405	CcSEcCtD
Tacrolimus—FKBP1A—lymph node—thymus cancer	0.00283	0.0108	CbGeAlD
Tacrolimus—Depression—Octreotide—thymus cancer	0.00283	0.00402	CcSEcCtD
Tacrolimus—Neuropathy peripheral—Octreotide—thymus cancer	0.00278	0.00395	CcSEcCtD
Tacrolimus—Jaundice—Octreotide—thymus cancer	0.00276	0.00393	CcSEcCtD
Tacrolimus—Conjunctivitis—Octreotide—thymus cancer	0.00276	0.00392	CcSEcCtD
Tacrolimus—Urinary tract infection—Octreotide—thymus cancer	0.00276	0.00392	CcSEcCtD
Tacrolimus—Haematuria—Octreotide—thymus cancer	0.0027	0.00384	CcSEcCtD
Tacrolimus—Hepatobiliary disease—Octreotide—thymus cancer	0.00268	0.00381	CcSEcCtD
Tacrolimus—Epistaxis—Octreotide—thymus cancer	0.00267	0.0038	CcSEcCtD
Tacrolimus—Sinusitis—Octreotide—thymus cancer	0.00266	0.00378	CcSEcCtD
Tacrolimus—Bradycardia—Octreotide—thymus cancer	0.00259	0.00368	CcSEcCtD
Tacrolimus—Rhinitis—Octreotide—thymus cancer	0.00255	0.00363	CcSEcCtD
Tacrolimus—Hepatitis—Octreotide—thymus cancer	0.00254	0.00362	CcSEcCtD
Tacrolimus—Hypoaesthesia—Octreotide—thymus cancer	0.00253	0.0036	CcSEcCtD
Tacrolimus—Pharyngitis—Octreotide—thymus cancer	0.00253	0.00359	CcSEcCtD
Tacrolimus—Oedema peripheral—Octreotide—thymus cancer	0.00251	0.00356	CcSEcCtD
Tacrolimus—Visual impairment—Octreotide—thymus cancer	0.00245	0.00349	CcSEcCtD
Tacrolimus—PPP3CA—T-Cell Receptor and Co-stimulatory Signaling—CD8A—thymus cancer	0.00243	0.0697	CbGpPWpGaD
Tacrolimus—Tinnitus—Octreotide—thymus cancer	0.00237	0.00337	CcSEcCtD
Tacrolimus—Flushing—Octreotide—thymus cancer	0.00236	0.00336	CcSEcCtD
Tacrolimus—Cardiac disorder—Octreotide—thymus cancer	0.00236	0.00336	CcSEcCtD
Tacrolimus—CYP3A4—hematopoietic system—thymus cancer	0.00233	0.0089	CbGeAlD
Tacrolimus—Immune system disorder—Octreotide—thymus cancer	0.0023	0.00327	CcSEcCtD
Tacrolimus—Arrhythmia—Octreotide—thymus cancer	0.00227	0.00323	CcSEcCtD
Tacrolimus—Alopecia—Octreotide—thymus cancer	0.00225	0.0032	CcSEcCtD
Tacrolimus—Mental disorder—Octreotide—thymus cancer	0.00223	0.00317	CcSEcCtD
Tacrolimus—ORM1—lymph node—thymus cancer	0.00222	0.00847	CbGeAlD
Tacrolimus—Malnutrition—Octreotide—thymus cancer	0.00221	0.00315	CcSEcCtD
Tacrolimus—Erythema—Octreotide—thymus cancer	0.00221	0.00315	CcSEcCtD
Tacrolimus—Flatulence—Octreotide—thymus cancer	0.00218	0.0031	CcSEcCtD
Tacrolimus—Tension—Octreotide—thymus cancer	0.00217	0.00309	CcSEcCtD
Tacrolimus—Nervousness—Octreotide—thymus cancer	0.00215	0.00306	CcSEcCtD
Tacrolimus—Back pain—Octreotide—thymus cancer	0.00214	0.00305	CcSEcCtD
Tacrolimus—Muscle spasms—Octreotide—thymus cancer	0.00213	0.00303	CcSEcCtD
Tacrolimus—Vision blurred—Octreotide—thymus cancer	0.00209	0.00297	CcSEcCtD
Tacrolimus—Tremor—Octreotide—thymus cancer	0.00208	0.00295	CcSEcCtD
Tacrolimus—Ill-defined disorder—Octreotide—thymus cancer	0.00206	0.00292	CcSEcCtD
Tacrolimus—Anaemia—Octreotide—thymus cancer	0.00205	0.00291	CcSEcCtD
Tacrolimus—Agitation—Octreotide—thymus cancer	0.00204	0.00289	CcSEcCtD
Tacrolimus—Malaise—Octreotide—thymus cancer	0.002	0.00284	CcSEcCtD
Tacrolimus—Vertigo—Octreotide—thymus cancer	0.00199	0.00283	CcSEcCtD
Tacrolimus—Syncope—Octreotide—thymus cancer	0.00199	0.00282	CcSEcCtD
Tacrolimus—Palpitations—Octreotide—thymus cancer	0.00196	0.00278	CcSEcCtD
Tacrolimus—Loss of consciousness—Octreotide—thymus cancer	0.00195	0.00277	CcSEcCtD
Tacrolimus—ALB—lymph node—thymus cancer	0.00194	0.00743	CbGeAlD
Tacrolimus—Cough—Octreotide—thymus cancer	0.00193	0.00275	CcSEcCtD
Tacrolimus—Convulsion—Octreotide—thymus cancer	0.00192	0.00273	CcSEcCtD
Tacrolimus—Hypertension—Octreotide—thymus cancer	0.00191	0.00272	CcSEcCtD
Tacrolimus—Myalgia—Octreotide—thymus cancer	0.00189	0.00268	CcSEcCtD
Tacrolimus—Arthralgia—Octreotide—thymus cancer	0.00189	0.00268	CcSEcCtD
Tacrolimus—Chest pain—Octreotide—thymus cancer	0.00189	0.00268	CcSEcCtD
Tacrolimus—Anxiety—Octreotide—thymus cancer	0.00188	0.00267	CcSEcCtD
Tacrolimus—Unspecified disorder of skin and subcutaneous tissue—Octreotide—thymus cancer	0.00187	0.00266	CcSEcCtD
Tacrolimus—Discomfort—Octreotide—thymus cancer	0.00186	0.00265	CcSEcCtD
Tacrolimus—Dry mouth—Octreotide—thymus cancer	0.00184	0.00262	CcSEcCtD
Tacrolimus—Anaphylactic shock—Octreotide—thymus cancer	0.00181	0.00257	CcSEcCtD
Tacrolimus—Oedema—Octreotide—thymus cancer	0.00181	0.00257	CcSEcCtD
Tacrolimus—CYP3A5—lung—thymus cancer	0.0018	0.00689	CbGeAlD
Tacrolimus—Infection—Octreotide—thymus cancer	0.0018	0.00255	CcSEcCtD
Tacrolimus—Shock—Octreotide—thymus cancer	0.00178	0.00253	CcSEcCtD
Tacrolimus—Nervous system disorder—Octreotide—thymus cancer	0.00177	0.00252	CcSEcCtD
Tacrolimus—Thrombocytopenia—Octreotide—thymus cancer	0.00177	0.00252	CcSEcCtD
Tacrolimus—Tachycardia—Octreotide—thymus cancer	0.00176	0.00251	CcSEcCtD
Tacrolimus—Skin disorder—Octreotide—thymus cancer	0.00176	0.0025	CcSEcCtD
Tacrolimus—Hyperhidrosis—Octreotide—thymus cancer	0.00175	0.00248	CcSEcCtD
Tacrolimus—Anorexia—Octreotide—thymus cancer	0.00172	0.00245	CcSEcCtD
Tacrolimus—ABCB1—hematopoietic system—thymus cancer	0.00165	0.0063	CbGeAlD
Tacrolimus—Musculoskeletal discomfort—Octreotide—thymus cancer	0.00165	0.00234	CcSEcCtD
Tacrolimus—Insomnia—Octreotide—thymus cancer	0.00164	0.00232	CcSEcCtD
Tacrolimus—Paraesthesia—Octreotide—thymus cancer	0.00162	0.00231	CcSEcCtD
Tacrolimus—Dyspnoea—Octreotide—thymus cancer	0.00161	0.00229	CcSEcCtD
Tacrolimus—Somnolence—Octreotide—thymus cancer	0.00161	0.00228	CcSEcCtD
Tacrolimus—Dyspepsia—Octreotide—thymus cancer	0.00159	0.00226	CcSEcCtD
Tacrolimus—Decreased appetite—Octreotide—thymus cancer	0.00157	0.00223	CcSEcCtD
Tacrolimus—Gastrointestinal disorder—Octreotide—thymus cancer	0.00156	0.00222	CcSEcCtD
Tacrolimus—Fatigue—Octreotide—thymus cancer	0.00156	0.00222	CcSEcCtD
Tacrolimus—Constipation—Octreotide—thymus cancer	0.00155	0.0022	CcSEcCtD
Tacrolimus—Pain—Octreotide—thymus cancer	0.00155	0.0022	CcSEcCtD
Tacrolimus—ABCB1—epithelium—thymus cancer	0.00151	0.00576	CbGeAlD
Tacrolimus—Feeling abnormal—Octreotide—thymus cancer	0.00149	0.00212	CcSEcCtD
Tacrolimus—Gastrointestinal pain—Octreotide—thymus cancer	0.00148	0.0021	CcSEcCtD
Tacrolimus—Urticaria—Octreotide—thymus cancer	0.00144	0.00204	CcSEcCtD
Tacrolimus—Abdominal pain—Octreotide—thymus cancer	0.00143	0.00203	CcSEcCtD
Tacrolimus—Body temperature increased—Octreotide—thymus cancer	0.00143	0.00203	CcSEcCtD
Tacrolimus—Hypersensitivity—Octreotide—thymus cancer	0.00133	0.00189	CcSEcCtD
Tacrolimus—Asthenia—Octreotide—thymus cancer	0.0013	0.00184	CcSEcCtD
Tacrolimus—PPP3CA—T-Cell Receptor and Co-stimulatory Signaling—IL2—thymus cancer	0.00129	0.0368	CbGpPWpGaD
Tacrolimus—Pruritus—Octreotide—thymus cancer	0.00128	0.00182	CcSEcCtD
Tacrolimus—Diarrhoea—Octreotide—thymus cancer	0.00124	0.00176	CcSEcCtD
Tacrolimus—ABCB1—pituitary gland—thymus cancer	0.00122	0.00468	CbGeAlD
Tacrolimus—Dizziness—Octreotide—thymus cancer	0.0012	0.0017	CcSEcCtD
Tacrolimus—ABCB1—lymphoid tissue—thymus cancer	0.00116	0.00444	CbGeAlD
Tacrolimus—Vomiting—Octreotide—thymus cancer	0.00115	0.00163	CcSEcCtD
Tacrolimus—Rash—Octreotide—thymus cancer	0.00114	0.00162	CcSEcCtD
Tacrolimus—Dermatitis—Octreotide—thymus cancer	0.00114	0.00162	CcSEcCtD
Tacrolimus—Headache—Octreotide—thymus cancer	0.00113	0.00161	CcSEcCtD
Tacrolimus—Nausea—Octreotide—thymus cancer	0.00107	0.00153	CcSEcCtD
Tacrolimus—ABCB1—bone marrow—thymus cancer	0.00106	0.00404	CbGeAlD
Tacrolimus—ABCB1—thyroid gland—thymus cancer	0.00105	0.00403	CbGeAlD
Tacrolimus—FKBP1A—Calcium signaling in the CD4+ TCR pathway—IL2—thymus cancer	0.000997	0.0286	CbGpPWpGaD
Tacrolimus—ABCB1—lung—thymus cancer	0.000957	0.00366	CbGeAlD
Tacrolimus—PPP3CA—C-MYB transcription factor network—KIT—thymus cancer	0.000781	0.0224	CbGpPWpGaD
Tacrolimus—PPP3CA—T-Cell Receptor and Co-stimulatory Signaling—AKT1—thymus cancer	0.000697	0.02	CbGpPWpGaD
Tacrolimus—PPP3CA—Amyotrophic lateral sclerosis (ALS)—TP53—thymus cancer	0.000665	0.0191	CbGpPWpGaD
Tacrolimus—ABCB1—lymph node—thymus cancer	0.000655	0.0025	CbGeAlD
Tacrolimus—PPP3CA—C-MYB transcription factor network—CDKN2A—thymus cancer	0.000634	0.0182	CbGpPWpGaD
Tacrolimus—PPP3CA—C-MYB transcription factor network—CD4—thymus cancer	0.000597	0.0171	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—CD8A—thymus cancer	0.000593	0.017	CbGpPWpGaD
Tacrolimus—MTOR—IL2 signaling events mediated by PI3K—IL2—thymus cancer	0.000462	0.0132	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—CYLD—thymus cancer	0.000456	0.013	CbGpPWpGaD
Tacrolimus—FKBP1A—TOR Signaling—AKT1—thymus cancer	0.000455	0.013	CbGpPWpGaD
Tacrolimus—PPP3CA—Fc epsilon receptor (FCERI) signaling—KIT—thymus cancer	0.00043	0.0123	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—IL2—thymus cancer	0.000419	0.012	CbGpPWpGaD
Tacrolimus—PPP3CA—Cardiac Hypertrophic Response—AKT1—thymus cancer	0.000418	0.012	CbGpPWpGaD
Tacrolimus—MTOR—CD28 dependent PI3K/Akt signaling—AKT1—thymus cancer	0.000394	0.0113	CbGpPWpGaD
Tacrolimus—PPP3CA—Alzheimers Disease—TP53—thymus cancer	0.00037	0.0106	CbGpPWpGaD
Tacrolimus—PPP3CA—BCR signaling pathway—AKT1—thymus cancer	0.000357	0.0102	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—CD4—thymus cancer	0.000341	0.00976	CbGpPWpGaD
Tacrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—KIT—thymus cancer	0.000334	0.00957	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—IL2—thymus cancer	0.000325	0.00929	CbGpPWpGaD
Tacrolimus—MTOR—FSH signaling pathway—AKT1—thymus cancer	0.000322	0.00922	CbGpPWpGaD
Tacrolimus—MTOR—IL12-mediated signaling events—IL2—thymus cancer	0.000314	0.00898	CbGpPWpGaD
Tacrolimus—MTOR—VEGFR2 mediated vascular permeability—AKT1—thymus cancer	0.000313	0.00896	CbGpPWpGaD
Tacrolimus—MTOR—Costimulation by the CD28 family—CD4—thymus cancer	0.000308	0.00883	CbGpPWpGaD
Tacrolimus—MTOR—PI-3K cascade—KIT—thymus cancer	0.000301	0.00862	CbGpPWpGaD
Tacrolimus—PPP3CA—MicroRNAs in cardiomyocyte hypertrophy—AKT1—thymus cancer	0.000298	0.00853	CbGpPWpGaD
Tacrolimus—MTOR—Extracellular vesicle-mediated signaling in recipient cells—AKT1—thymus cancer	0.000296	0.00848	CbGpPWpGaD
Tacrolimus—MTOR—PI3K/AKT activation—KIT—thymus cancer	0.000294	0.00841	CbGpPWpGaD
Tacrolimus—MTOR—GAB1 signalosome—KIT—thymus cancer	0.000291	0.00835	CbGpPWpGaD
Tacrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—KIT—thymus cancer	0.000285	0.00816	CbGpPWpGaD
Tacrolimus—MTOR—Regulation of Telomerase—IL2—thymus cancer	0.000284	0.00812	CbGpPWpGaD
Tacrolimus—MTOR—CD28 co-stimulation—AKT1—thymus cancer	0.000281	0.00805	CbGpPWpGaD
Tacrolimus—MTOR—Alpha 6 Beta 4 signaling pathway—AKT1—thymus cancer	0.000274	0.00786	CbGpPWpGaD
Tacrolimus—PPP3CA—Spinal Cord Injury—TP53—thymus cancer	0.000269	0.0077	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CYLD—thymus cancer	0.000265	0.0076	CbGpPWpGaD
Tacrolimus—MTOR—LKB1 signaling events—TP53—thymus cancer	0.000263	0.00753	CbGpPWpGaD
Tacrolimus—MTOR—Class I PI3K signaling events mediated by Akt—AKT1—thymus cancer	0.000262	0.00749	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—CD4—thymus cancer	0.00026	0.00746	CbGpPWpGaD
Tacrolimus—MTOR—TOR Signaling—AKT1—thymus cancer	0.000256	0.00733	CbGpPWpGaD
Tacrolimus—MTOR—IL2 signaling events mediated by PI3K—AKT1—thymus cancer	0.00025	0.00717	CbGpPWpGaD
Tacrolimus—MTOR—CXCR3-mediated signaling events—AKT1—thymus cancer	0.000245	0.00702	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—CDKN2A—thymus cancer	0.000231	0.00662	CbGpPWpGaD
Tacrolimus—MTOR—ErbB2/ErbB3 signaling events—AKT1—thymus cancer	0.000231	0.0066	CbGpPWpGaD
Tacrolimus—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—KIT—thymus cancer	0.000226	0.00646	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—KIT—thymus cancer	0.000225	0.00644	CbGpPWpGaD
Tacrolimus—MTOR—IFN-gamma pathway—AKT1—thymus cancer	0.000222	0.00636	CbGpPWpGaD
Tacrolimus—MTOR—ErbB Signaling Pathway—TP53—thymus cancer	0.000219	0.00627	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—KIT—thymus cancer	0.000215	0.00616	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—KIT—thymus cancer	0.000212	0.00607	CbGpPWpGaD
Tacrolimus—FKBP1A—Spinal Cord Injury—TP53—thymus cancer	0.000208	0.00597	CbGpPWpGaD
Tacrolimus—MTOR—TSLP Signaling Pathway—AKT1—thymus cancer	0.000207	0.00592	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—TP53—thymus cancer	0.000203	0.0058	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—KIT—thymus cancer	0.000202	0.00579	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—KIT—thymus cancer	0.000201	0.00576	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—KIT—thymus cancer	0.0002	0.00574	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—KIT—thymus cancer	0.000199	0.00571	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CYLD—thymus cancer	0.000199	0.00569	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—KIT—thymus cancer	0.000196	0.00563	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—MAML2—thymus cancer	0.000195	0.00557	CbGpPWpGaD
Tacrolimus—MTOR—Wnt Signaling Pathway Netpath—AKT1—thymus cancer	0.000191	0.00546	CbGpPWpGaD
Tacrolimus—MTOR—Oncostatin M Signaling Pathway—TP53—thymus cancer	0.000189	0.00541	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—KIT—thymus cancer	0.000188	0.00537	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—KIT—thymus cancer	0.000188	0.00537	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—KIT—thymus cancer	0.000188	0.00537	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—KIT—thymus cancer	0.000186	0.00532	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—KIT—thymus cancer	0.000184	0.00528	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—KIT—thymus cancer	0.000183	0.00525	CbGpPWpGaD
Tacrolimus—MTOR—Cardiac Hypertrophic Response—AKT1—thymus cancer	0.000182	0.00522	CbGpPWpGaD
Tacrolimus—MTOR—RANKL/RANK Signaling Pathway—AKT1—thymus cancer	0.000182	0.00522	CbGpPWpGaD
Tacrolimus—MTOR—AMPK Signaling—TP53—thymus cancer	0.00018	0.00516	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—KIT—thymus cancer	0.000174	0.00497	CbGpPWpGaD
Tacrolimus—PPP3CA—MAPK Signaling Pathway—AKT1—thymus cancer	0.000171	0.0049	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—KIT—thymus cancer	0.000167	0.00478	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—KIT—thymus cancer	0.000166	0.00476	CbGpPWpGaD
Tacrolimus—MTOR—IL4-mediated signaling events—AKT1—thymus cancer	0.000166	0.00474	CbGpPWpGaD
Tacrolimus—PPP3CA—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	0.000164	0.0047	CbGpPWpGaD
Tacrolimus—MTOR—Oncostatin M Signaling Pathway—AKT1—thymus cancer	0.000159	0.00457	CbGpPWpGaD
Tacrolimus—MTOR—mTOR signaling pathway—AKT1—thymus cancer	0.000158	0.00451	CbGpPWpGaD
Tacrolimus—MTOR—TSH signaling pathway—AKT1—thymus cancer	0.000158	0.00451	CbGpPWpGaD
Tacrolimus—MTOR—Regulation of Telomerase—AKT1—thymus cancer	0.000154	0.00441	CbGpPWpGaD
Tacrolimus—MTOR—Costimulation by the CD28 family—AKT1—thymus cancer	0.000154	0.00441	CbGpPWpGaD
Tacrolimus—MTOR—AMPK Signaling—AKT1—thymus cancer	0.000152	0.00435	CbGpPWpGaD
Tacrolimus—MTOR—SREBP signalling—AKT1—thymus cancer	0.000152	0.00435	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—MAML2—thymus cancer	0.000151	0.00432	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—IL2—thymus cancer	0.000143	0.00409	CbGpPWpGaD
Tacrolimus—MTOR—Leptin signaling pathway—AKT1—thymus cancer	0.000142	0.00407	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	0.000142	0.00406	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—MAML2—thymus cancer	0.000136	0.0039	CbGpPWpGaD
Tacrolimus—MTOR—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—AKT1—thymus cancer	0.000135	0.00387	CbGpPWpGaD
Tacrolimus—PPP3CA—RNF mutants show enhanced WNT signaling and proliferation—AKT1—thymus cancer	0.000134	0.00385	CbGpPWpGaD
Tacrolimus—MTOR—CXCR4-mediated signaling events—AKT1—thymus cancer	0.00013	0.00372	CbGpPWpGaD
Tacrolimus—MTOR—MicroRNAs in cardiomyocyte hypertrophy—AKT1—thymus cancer	0.00013	0.00372	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD8A—thymus cancer	0.00013	0.00371	CbGpPWpGaD
Tacrolimus—MTOR—Senescence and Autophagy in Cancer—TP53—thymus cancer	0.000129	0.00369	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—CD4—thymus cancer	0.000128	0.00366	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—KIT—thymus cancer	0.000128	0.00366	CbGpPWpGaD
Tacrolimus—MTOR—Constitutive PI3K/AKT Signaling in Cancer—AKT1—thymus cancer	0.000127	0.00365	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by WNT in cancer—AKT1—thymus cancer	0.000125	0.00358	CbGpPWpGaD
Tacrolimus—FKBP1A—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	0.00012	0.00343	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CYLD—thymus cancer	0.000116	0.00331	CbGpPWpGaD
Tacrolimus—MTOR—PI-3K cascade—AKT1—thymus cancer	0.000115	0.00329	CbGpPWpGaD
Tacrolimus—MTOR—PI3K/AKT activation—AKT1—thymus cancer	0.000112	0.00321	CbGpPWpGaD
Tacrolimus—MTOR—GAB1 signalosome—AKT1—thymus cancer	0.000111	0.00318	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—CDKN2A—thymus cancer	0.000111	0.00317	CbGpPWpGaD
Tacrolimus—MTOR—ErbB1 downstream signaling—AKT1—thymus cancer	0.000109	0.00311	CbGpPWpGaD
Tacrolimus—MTOR—Role of LAT2/NTAL/LAB on calcium mobilization—AKT1—thymus cancer	0.000109	0.00311	CbGpPWpGaD
Tacrolimus—ABCB1—Allograft Rejection—IL2—thymus cancer	0.000108	0.0031	CbGpPWpGaD
Tacrolimus—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—thymus cancer	0.000107	0.00307	CbGpPWpGaD
Tacrolimus—MTOR—VEGFA-VEGFR2 Pathway—AKT1—thymus cancer	0.000107	0.00307	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—MAML2—thymus cancer	0.000106	0.00303	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by Wnt—AKT1—thymus cancer	0.000103	0.00295	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by VEGF—AKT1—thymus cancer	0.000101	0.00289	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—KIT—thymus cancer	9.73e-05	0.00279	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—TP53—thymus cancer	9.62e-05	0.00276	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD8A—thymus cancer	9.32e-05	0.00267	CbGpPWpGaD
Tacrolimus—ALB—Folate Metabolism—TP53—thymus cancer	9.17e-05	0.00263	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—KIT—thymus cancer	8.98e-05	0.00257	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by SCF-KIT—AKT1—thymus cancer	8.58e-05	0.00246	CbGpPWpGaD
Tacrolimus—MTOR—Disease—MAML2—thymus cancer	8.49e-05	0.00243	CbGpPWpGaD
Tacrolimus—MTOR—BDNF signaling pathway—AKT1—thymus cancer	8.44e-05	0.00242	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling of activated FGFR—AKT1—thymus cancer	8.21e-05	0.00235	CbGpPWpGaD
Tacrolimus—MTOR—Integrated Breast Cancer Pathway—AKT1—thymus cancer	8.13e-05	0.00233	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB4—AKT1—thymus cancer	8.08e-05	0.00231	CbGpPWpGaD
Tacrolimus—MTOR—Insulin Signaling—AKT1—thymus cancer	7.76e-05	0.00222	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signal transduction—AKT1—thymus cancer	7.72e-05	0.00221	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR—AKT1—thymus cancer	7.68e-05	0.0022	CbGpPWpGaD
Tacrolimus—MTOR—EGF/EGFR Signaling Pathway—AKT1—thymus cancer	7.68e-05	0.0022	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by ERBB2—AKT1—thymus cancer	7.64e-05	0.00219	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 signaling—AKT1—thymus cancer	7.61e-05	0.00218	CbGpPWpGaD
Tacrolimus—MTOR—Downstream signaling events of B Cell Receptor (BCR)—AKT1—thymus cancer	7.5e-05	0.00215	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—IL2—thymus cancer	7.49e-05	0.00215	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—CD4—thymus cancer	7.44e-05	0.00213	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—KIT—thymus cancer	7.29e-05	0.00209	CbGpPWpGaD
Tacrolimus—MTOR—DAP12 interactions—AKT1—thymus cancer	7.16e-05	0.00205	CbGpPWpGaD
Tacrolimus—MTOR—Fc epsilon receptor (FCERI) signaling—AKT1—thymus cancer	7.16e-05	0.00205	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by FGFR in disease—AKT1—thymus cancer	7.16e-05	0.00205	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR—AKT1—thymus cancer	7.09e-05	0.00203	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by EGFR in Cancer—AKT1—thymus cancer	7.03e-05	0.00201	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by PDGF—AKT1—thymus cancer	7e-05	0.002	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—KIT—thymus cancer	7e-05	0.002	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—KIT—thymus cancer	6.97e-05	0.002	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—CD4—thymus cancer	6.87e-05	0.00197	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—IL2—thymus cancer	6.85e-05	0.00196	CbGpPWpGaD
Tacrolimus—ABCB1—HIF-1-alpha transcription factor network—AKT1—thymus cancer	6.78e-05	0.00194	CbGpPWpGaD
Tacrolimus—MTOR—B Cell Activation—AKT1—thymus cancer	6.62e-05	0.0019	CbGpPWpGaD
Tacrolimus—PPP3CA—Innate Immune System—AKT1—thymus cancer	6.38e-05	0.00183	CbGpPWpGaD
Tacrolimus—MTOR—NGF signalling via TRKA from the plasma membrane—AKT1—thymus cancer	6.34e-05	0.00182	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—KIT—thymus cancer	6.29e-05	0.0018	CbGpPWpGaD
Tacrolimus—MTOR—Cellular responses to stress—TP53—thymus cancer	6.15e-05	0.00176	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—MAML2—thymus cancer	5.94e-05	0.0017	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD8A—thymus cancer	5.65e-05	0.00162	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—CD4—thymus cancer	5.57e-05	0.0016	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—IL2—thymus cancer	5.43e-05	0.00155	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—CD4—thymus cancer	5.35e-05	0.00153	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—CD4—thymus cancer	5.33e-05	0.00153	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—KIT—thymus cancer	4.88e-05	0.0014	CbGpPWpGaD
Tacrolimus—MTOR—Signaling by NGF—AKT1—thymus cancer	4.87e-05	0.0014	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—IL2—thymus cancer	4.43e-05	0.00127	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—KIT—thymus cancer	4.24e-05	0.00122	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling by GPCR—AKT1—thymus cancer	4.06e-05	0.00116	CbGpPWpGaD
Tacrolimus—MTOR—Disease—KIT—thymus cancer	3.92e-05	0.00112	CbGpPWpGaD
Tacrolimus—PPP3CA—Immune System—AKT1—thymus cancer	3.71e-05	0.00106	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—IL2—thymus cancer	3.43e-05	0.000983	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—thymus cancer	3.43e-05	0.000983	CbGpPWpGaD
Tacrolimus—PPP3CA—Disease—AKT1—thymus cancer	3.43e-05	0.000982	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—CD4—thymus cancer	3.25e-05	0.00093	CbGpPWpGaD
Tacrolimus—MTOR—Disease—CD4—thymus cancer	3e-05	0.000858	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—IL2—thymus cancer	2.99e-05	0.000855	CbGpPWpGaD
Tacrolimus—ALB—Platelet activation, signaling and aggregation—AKT1—thymus cancer	2.94e-05	0.000843	CbGpPWpGaD
Tacrolimus—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—thymus cancer	2.9e-05	0.00083	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—TP53—thymus cancer	2.84e-05	0.000814	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—IL2—thymus cancer	2.8e-05	0.000801	CbGpPWpGaD
Tacrolimus—MTOR—Innate Immune System—AKT1—thymus cancer	2.78e-05	0.000796	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—KIT—thymus cancer	2.74e-05	0.000786	CbGpPWpGaD
Tacrolimus—MTOR—Adaptive Immune System—AKT1—thymus cancer	2.67e-05	0.000765	CbGpPWpGaD
Tacrolimus—FKBP1A—Disease—AKT1—thymus cancer	2.66e-05	0.000761	CbGpPWpGaD
Tacrolimus—PPP3CA—Signaling Pathways—AKT1—thymus cancer	2.4e-05	0.000688	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—TP53—thymus cancer	2.2e-05	0.000631	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—IL2—thymus cancer	1.93e-05	0.000553	CbGpPWpGaD
Tacrolimus—FKBP1A—Signaling Pathways—AKT1—thymus cancer	1.86e-05	0.000533	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—TP53—thymus cancer	1.8e-05	0.000515	CbGpPWpGaD
Tacrolimus—MTOR—Immune System—AKT1—thymus cancer	1.62e-05	0.000464	CbGpPWpGaD
Tacrolimus—ALB—Hemostasis—AKT1—thymus cancer	1.52e-05	0.000435	CbGpPWpGaD
Tacrolimus—MTOR—Disease—AKT1—thymus cancer	1.5e-05	0.000428	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—TP53—thymus cancer	1.24e-05	0.000355	CbGpPWpGaD
Tacrolimus—MTOR—Signaling Pathways—AKT1—thymus cancer	1.05e-05	0.0003	CbGpPWpGaD
Tacrolimus—CYP3A7—Metabolism—AKT1—thymus cancer	9.88e-06	0.000283	CbGpPWpGaD
Tacrolimus—CYP3A5—Metabolism—AKT1—thymus cancer	7.14e-06	0.000205	CbGpPWpGaD
Tacrolimus—ALB—Metabolism—AKT1—thymus cancer	6.15e-06	0.000176	CbGpPWpGaD
Tacrolimus—ABCB1—Metabolism—AKT1—thymus cancer	5.39e-06	0.000154	CbGpPWpGaD
Tacrolimus—CYP3A4—Metabolism—AKT1—thymus cancer	3.32e-06	9.51e-05	CbGpPWpGaD
